Supplementary Figure S3 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas | Synapse
July 15, 2025
Supplementary Figure S3 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
Puntos clave
MAIN FINDING: The study evaluates the effectiveness of doxorubicin with zalifrelimab and balstilimab in advanced soft tissue sarcomas.
KEY EVIDENCE: Post-hoc analysis demonstrates significant differences in clinical outcomes between stage 1 and stage 2.
APPROACH: A single-arm phase 2 trial assessed treatment responses from patients receiving combined immunotherapy and chemotherapy.
SIGNIFICANCE: This research may enhance treatment strategies for patients with advanced soft tissue sarcomas by integrating immunotherapies.